Skip to main content

Laxatives Cure Bed-Wetting for Many Children

January 31, 2012 — Laxatives are the answer for many children experiencing bed-wetting, according to a report from Wake Forest University in Winston-Salem, North Carolina. Investigators report that occult megarectum is a commonly overlooked cause of nocturnal enuresis, and that it can be detected simply by an abdominal X-ray and treated with laxatives.
Lead author Steve Hodges, MD, assistant professor of urology, and coauthor Evelyn Anthony, MD, from the Department of Radiology at the university, found that 30 children and adolescents aged 5 to 15 years seeking treatment for bed-wetting had large amounts of stool in their rectums, even though they reported having normal bowel habits. The report, published online December 14 in Urology, showed that 3 months of laxative therapy cured 25 patients (83%) of their bed-wetting.
The authors note that stool retention reduces bladder capacity (and possibly leads to bladder overactivity) and explains why many therapies aimed at the bladder, such as fluid restriction or alarms, may be ineffective.
A landmark study performed more than 25 years ago showed that constipation, defined as abnormal rectal distension, was a commonly unrecognized cause of enuresis. However, those findings did little to change practice. This definition of constipation differs from that of the International Children's Continence Society (ICCS) guidelines, which rely on bowel habits and stool consistency. The researchers hypothesized that undiagnosed megarectum underlies many cases of nocturnal enuresis, and that laxative treatment may be effective.
They performed a retrospective review of 30 consecutive patients (19 boys and 11 girls) seen in their clinic who presented with a chief complaint of nighttime enuresis. They used a novel method to determine the rectal/pelvic outlet ratio and the Leech criteria for assessing fecal loading, using a plain abdominal radiograph, and compared these findings with the reported constipation history according to the ICCS guidelines. According to the guidelines, a diagnosis of constipation is made based on parents' and children's reports of a bowel movement less frequently than every other day, and on whether the stool consistency is hard.
The rectal/pelvic outlet ratio is the ratio of the maximum diameter of the rectum when distended by stool, divided by the diameter of the pelvic outlet between the obturator stripes at the level of the femoral heads.
All the patients showed rectal distension, based on a rectal/pelvic ratio greater than 1, and 80% met the Leech criteria for constipation. Only 3 of the children or families (10%) described bowel habits consistent with constipation. There was a statistically significant difference between the radiographic findings for fecal loading by the Leech criteria and self-reported constipation (P < .001), with the radiographic findings revealing otherwise unknown constipation. For example, for 27 cases in which the self-reports were negative, radiographs showed constipation in 21.
Initial therapy was a bowel clean-out with polyethylene glycol 3350 laxative (PEG), followed by a daily maintenance dose "titrated to keep the stools the consistency of a milk shake," the authors write. If follow-up imaging at 1 and 3 months showed persistent megarectum, daily phosphate enemas or stimulant laxatives were added to the PEG regimen.
The researchers reported that all of the 4 adolescents and 80% of the younger children in the study were cured of their enuresis by these methods. Persistent enuresis at 3 months with no rectal stool on X-ray was considered a treatment failure.
Because some of the cases may have improved over time on their own, a more rigorous test of the efficacy of laxative therapy would require a randomized trial assigning some constipated children to the therapy and others to an inactive therapy, Dr. Hodges noted in a press release from Wake Forest University. He also advised that any medical therapy for bed-wetting be done under the supervision of a physician.
Proper treatment in many cases may require the recognition of occult megarectum, and physicians would do well to focus on rectal distension, and not just functional constipation. In addition to X-ray, Dr. Hodges suggested, in the press release, that rectal distension could also be determined using rectal ultrasonography, with the advantage of avoiding ionizing radiation. He emphasized the importance of a correct diagnosis to avoid unnecessary surgery and the adverse effects of medication (such as desmopressin), and he urged physicians to first obtain an X-ray or ultrasound.
Dr. Hodges has disclosed no relevant financial relationships

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...